Loading…
TEVA-NAPROXEN is a brand name for Naproxen, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: TEVA-NAPROXEN (naproxen) is indicated for: The treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The relief of minor aches and pains in muscles, bones and joints, mild to moderate pain accompanied by inflammation in musculoskeletal injuries (sprains and…
Verbatim from this product's HC label. Tap a section to expand.
4 Geriatrics. 2 CONTRAINDICATIONS TEVA-NAPROXEN and TEVA-NAPROXEN EC Page 5 of 48 Naproxen is contraindicated in: the peri-operative setting of coronary artery bypass graft surgery (CABG). Although naproxen has NOT been studied in this patient population, a selective COX-2 inhibitor NSAID studied in such a setting has led to an increased incidence of cardiovascular/thromboembolic events, deep surgical infections and sternal wound complications.
the third trimester of pregnancy, because of risk of premature closure of the ductus arteriosus and prolonged parturition women who are breastfeeding, because of the potential for serious adverse reactions in nursing infants severe uncontrolled heart failure patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
For a complete listing, see
In addition, patients on 1500 mg/day need to be followed closely for the development of any adverse events. During long-term administration the dose of TEVA-NAPROXEN may be adjusted up or down depending on the clinical response of the patient.
A lower dose may suffice for long-term administration. TEVA-NAPROXEN and TEVA-NAPROXEN EC have not been studied in subjects under the age of 18. Analgesia/Musculoskeletal Injuries The recommended dose for naproxen is 250 mg three times a day or 375 mg twice a day.
This may be increased to 500 mg twice a day if needed. The lowest effective dose should be used. , enteric coated) are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed. Dysmenorrhea The recommended starting dose for naproxen is two 250 mg tablets (or one 500 mg tablet), followed by one 250 mg tablet every 6 - 8 hours, as required.
The total daily dose should not exceed 5 tablets (1250 mg). Alternatively, one 500 mg tablet given twice daily may be used. , enteric coated) are not recommended for initial treatment of acute pain because the absorption of naproxen is delayed.
Pediatrics (< 18 years of age):
Health Canada has not authorized an indication for pediatric use.
See 2 CONTRAINDICATIONS Geriatrics (>65 years of age):
In the elderly, frail and debilitated, the dosage should be reduced to the lowest level providing control of symptoms, and adjusted when necessary. 4 Geriatrics Renal impairment: A lower dose should be considered in patients with mild and moderate renal impairment.
5 mL/sec) or deteriorating renal disease (individuals with lesser degrees of renal impairment are at risk of deterioration of their renal function when prescribed NSAIDs and must be monitored).
1 Pregnant Women 08/2022 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ............................................................................................
2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION.................................................................
4 1 INDICATIONS .................................................................................................................. 1 Pediatrics ........................................................................................................................
2 Geriatrics ........................................................................................................................ 4 2 CONTRAINDICATIONS ......................................................................................................
4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ................................................................. 6 4 DOSAGE AND ADMINISTRATION ..................................................................................... 1 Dosing considerations ....................................................................................................
2 Recommended Dose and Dosage Adjustment .............................................................. 4 Administration ...............................................................................................................
5 Missed Dose ................................................................................................................... 9 5 OVERDOSAGE .................................................................................................................
1 Pregnant Women 08/2022 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ............................................................................................
2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION.................................................................
4 1 INDICATIONS .................................................................................................................. 1 Pediatrics ........................................................................................................................
2 Geriatrics ........................................................................................................................ 4 2 CONTRAINDICATIONS ......................................................................................................
4
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Naproxen in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
See 2 CONTRAINDICATIONS Hepatic impairment:
A lower dose should be considered in patients with mild and moderate hepatic impairment. TEVA-NAPROXEN and TEVA-NAPROXEN EC is contraindicated in severe liver impairment or active liver disease. 4 Administration TEVA-NAPROXEN EC tablet should be swallowed whole.
TEVA-NAPROXEN tablets should be swallowed with food or milk. 5 Missed Dose If a dose is missed, the patient should take it as soon as it is recognized. If it is almost time for the next dose, skip the missed dose and continue with the next scheduled dose.
The patient should be instructed not take 2 doses at the same time. 5 OVERDOSAGE Frequently observed signs and symptoms of overdose are drowsiness, dizziness, disorientation, heartburn, indigestion, epigastric pain, abdominal discomfort, nausea, vomiting, transient alterations in liver function, hypoprothrombinemia, renal dysfunction, metabolic acidosis and apnea.
A few patients have experienced convulsions, but it is not clear whether or not these were naproxen related. Gastrointestinal bleeding may occur. Hypertension, acute renal failure, respiratory depression and coma may occur after the ingestion of NSAIDs but are rare.
Anaphylactoid reactions have been repeated with therapeutic ingestion of NSAIDs, and may occur following an overdose. Patients should be managed by symptomatic and supportive care following NSAIDs overdose. There are no specific antidotes.
g. activated charcoal) may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large overdose. Forced diuresis, alkalinization of urine, haemodialysis, or haemoperfusion may not be useful due to high protein binding.
For management of a suspected drug overdose, contact your regional poison control centre. 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING Table 1 – Dosage Forms, Strengths, Composition and Packaging TEVA-NAPROXEN and TEVA-NAPROXEN EC Page 10 of 48 Route of Administration Dosage Form / Strength/ Composition Non-medicinal Ingredients Oral 250, 375 and 500 mg Enteric-Coated Tablets Chromateric White Deb 5018 WE, Colloidal Silicon Dioxide, Croscarmellose Sodium (Ac- Di-Sol), Dri Klear 042, Eudragit L30D, Magnesium Stearate, Povidone and Sodium Lauryl Sulphate Oral 250, 375 and 500 mg Tablets Colloidal silicon dioxide, FD&C yellow #6 lake 15-18% (HT), magnesium stearate, microcrystalline cellulose, povidone, sodium lauryl sulphate and sodium starch glycolate.
In addition, 250 mg & 500 mg Tablets have D&C yellow #10 lake 15-20% (HT).
TEVA-NAPROXEN (naproxen) is available as:
TEVA-NAPROXEN Tablets: 250 mg Yellow, football shaped, unscored tablets with "NOVO" on one side, "250" on the other side, containing 250 mg of naproxen. Bottles of 100 tablets. 375 mg Peach coloured, capsule shaped, engraved "NOVO" one side, "375" on reverse containing 375 mg of naproxen.
Bottles of 100 tablets. 500 mg Yellow coloured, capsule shaped, engraved "NOVO" bisect "500", plain on reverse, containing 500 mg of naproxen. Bottles of 100 and 500 tablets. TEVA-NAPROXEN Enteric-Coated Tablets: 250 mg White, round biconvex, enteric-coated tablet, printed in black on one side with “N” and “250” on the other side.
Available in bottles of 100. 375 mg White, capsule shaped, enteric coated tablet, printed in black on one side with “N” and “375” on the other side. Available in bottles of 100. TEVA-NAPROXEN and TEVA-NAPROXEN EC Page 11 of 48 500 mg White, capsule shaped, enteric coated tablet, printed in black on one side with “N” and “500” on the other side.
Available in bottles of 100. 7 WARNINGS AND PRECAUTIONS Please see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX General Frail or debilitated patients may tolerate side effects less well and therefore special care should be taken in treating this population.
To minimize the potential risk for an adverse event, the lowest effective dose should be used for the shortest possible […]
9 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ...................................... 9 7 WARNINGS AND PRECAUTIONS ..................................................................................... 1 Special Populations ......................................................................................................
1 Pregnant Women ......................................................................................................... 2 Breast-feeding ..............................................................................................................
3 Pediatrics ...................................................................................................................... 4 Geriatrics ......................................................................................................................
19 8 ADVERSE REACTIONS ..................................................................................................... 1 Adverse Reaction Overview .........................................................................................
2 Clinical Trial Adverse Reactions ................................................................................... 3 Less Common Clinical Trial Adverse Reactions ............................................................ 5 Post-Market Adverse Reactions...................................................................................
21 9 DRUG INTERACTIONS ..................................................................................................... 3 Drug-Behavioural Interactions .....................................................................................
4 Drug-Drug Interactions ................................................................................................ 5 Drug-Food Interactions.................................................................................................
6 Drug-Herb Interactions ................................................................................................ 7 Drug-Laboratory Interactions ......................................................................................
30 10 CLINICAL PHARMACOLOGY............................................................................................. 1 Mechanism of Action ...................................................................................................
2 Pharmacodynamics ...................................................................................................... 3 Pharmacokinetics .........................................................................................................
31 11 STORAGE, STABILITY AND DISPOSAL ............................................................................... 33 12 SPECIAL HANDLING INSTRUCTIONS ................................................................................
33 PART II: SCIENTIFIC INFORMATION........................................................................................ 34 13 PHARMACEUTICAL INFORMATION ...............................................................................
34 14 CLINICAL TRIALS ........................................................................................................... 3 Comparative Bioavailability Studies ............................................................................
35 15 MICROBIOLOGY ........................................................................................................... 37 16 NON-CLINICAL TOXICOLOGY ........................................................................................
37 17 SUPPORTING PRODUCT MONOGRAPH ......................................................................... 40 PATIENT MEDICATION INFORMATION................................................................................... 41 TEVA-NAPROXEN and TEVA-NAPROXEN EC Page 4 of 48 PART I: HEALTH PROFESSIONAL […]